Table 2.
Trait | Chr | BP* | SNP | EA | OA | Nearest locus | β (mmol/l/yr) | SE (mmol/l/yr) | β L95 (mmol/l/yr) | β U95 (mmol/l/yr) | P | Pheterogeneity | I2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ΔTC | 1 | 62912318 | chr1:62912318 | C | T | DOCK7/ANGPTL3 | −0.003 | 0.001 | −0.005 | −0.0004 | 0.02 | 0.39 | 0 |
ΔTC | 8 | 19669744 | rs13282247 | T | C | LPL/CSGALNACT1 | −0.003 | 0.001 | −0.006 | −0.001 | 0.02 | 0.39 | 0 |
ΔTC | 15 | 40469997 | chr15:40469997 | A | T | CAPN3 | 0.012 | 0.004 | 0.004 | 0.021 | 0.005 | 0.42 | 0 |
ΔTC | 16 | 70636491 | chr16:70636491 | T | G | HP/HPR | 0.011 | 0.004 | 0.002 | 0.02 | 0.01 | 0.04 | 0.69 |
ΔTC | 19 | 11001703 | rs17304534 | C | T | LDLR | −0.002 | 0.001 | −0.004 | −0.001 | 0.01 | 0.99 | 0 |
ΔTC | 19 | 50103919 | rs7412 | T | C | APOE/C1 | −0.012 | 0.002 | −0.016 | −0.007 | 1.5 × 10-7 | 0.81 | 0 |
ΔTG | 1 | 62954723 | chr1:62954723 | C | T | DOCK7/ANGPTL3 | −0.002 | 0.001 | −0.004 | −0.001 | 0.004 | 0.66 | 0 |
ΔTG | 8 | 126560154 | rs2954029 | T | A | TRIB1 | −0.003 | 0.001 | −0.004 | −0.001 | 2.4 × 10-4 | 0.47 | 0 |
ΔTG | 11 | 116167789 | rs651821 | C | T | ZNF159/APOA5/A1 | 0.008 | 0.002 | 0.005 | 0.011 | 3.6 × 10-7 | 0.06 | 0.60 |
ΔTG | 19 | 50848859 | rs10406431 | G | A | GIPR | −0.002 | 0.001 | −0.004 | −0.001 | 0.002 | 0.6 | 0 |
ΔTG | 19 | 50902205 | rs11668847 | G | T | QPCTL | −0.003 | 0.001 | −0.004 | −0.001 | 0.003 | 0.13 | 0.48 |
β - beta coefficient; β L95 - beta coefficient 95 % confidence interval lower border; β U95 - beta coefficient 95 % confidence interval upper border; BP - basepair position (Build36); Chr - chromosome; N - samples size; EA - effect allele; OA - other allele; SNP - single nucleotide polymorphism, TC - total cholesterol; TG - triglyceride.
Build36.
P values are obtained by fixed-effect inverse variance weighted meta-analysis.
Heterogeneity was measured by a Cochran's Q test. P value of this test and I2 statistics are reported.